HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations
US11767347B2 · kind B2 · utility
0Cited by
3References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2021 |
| Grant date | Sep 26, 2023 |
| Priority date | — |
| Expiry date | May 4, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.